We are happy to report that the first patient who enrolled in the "Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/​Refractory Lymphomas (IMMONC0001)" clinical trial is doing better, according to the PI of the study, Dr Atghik Voskanyan, and the Yeolyan Hematology and Oncology Center's hematology department staff.
This is our first investigator-initiated trial among patients with lymphoma, and it is going very well. In just 26 working days, the regulatory authorities approved the trial (NCT05891821), and participant recruitment is proceeding as planned. In less than 4 months, we have recruited 20% of the required number of participants—a shorter period than anticipated.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048